Innate immunity sensors participating in pathophysiology of joint diseases: A brief overview

Journal of Long-Term Effects of Medical Implants

Volumn 24, Issue 4, 2014, Pages 297-318

  Gallo, Jiri ^a   Raska, Milan ^a   Konttinen, Yrjö T ^b,c,d   Nich, Christophe ^e,f   Goodman, Stuart B ^g  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d University of Tampere   (Finland)

^e Paris university   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aseptic loosening; CLRs; Inflammasomes; Innate immunity sensors; NLRs; Osteoarthritis; PRRs; RAGE; Rheumatoid arthritis; TLRs

Indexed keywords

DISEASES; HISTOLOGY; IMMUNE SYSTEM; JOINT PROSTHESES; PATHOLOGY; TISSUE HOMEOSTASIS;

ASEPTIC LOOSENING; CLRS; INFLAMMASOMES; INNATE IMMUNITY; NLRS; OSTEOARTHRITIS; PRRS; RAGE; RHEUMATOID ARTHRITIS; TLRS;

TISSUE;

ADVANCED GLYCATION END PRODUCT; CALGRANULIN A; CALVASCULIN; CHEMOKINE RECEPTOR CXCR4; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 17; LEPTIN RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN KINASE SYK; PROTEIN S100B; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ADVANCED GLYCATION END PRODUCT RECEPTOR; CELL RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LECTIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN;

ARTHROPATHY; ARTICLE; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INNATE IMMUNITY; MOLECULAR SENSOR; NONHUMAN; OSTEOARTHRITIS; PROSTHESIS LOOSENING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; IMMUNOLOGY; JOINT PROSTHESIS; METABOLISM; OSTEOLYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNITY, INNATE; JOINT PROSTHESIS; LECTINS, C-TYPE; NOD SIGNALING ADAPTOR PROTEINS; OSTEOARTHRITIS; OSTEOLYSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTORS;

EID: 84911945900     PISSN: 10506934     EISSN: 19404379     Source Type: Journal    
DOI: 10.1615/jlongtermeffmedimplants.2014010825     Document Type: Article

References (181)

1. Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol. 2013;13:551–65.
2. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–35.
3. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol. 2009;9:692–703.
4. Medzhitov R. Approaching the asymptote: 20 years later. Immunity. 2009;30:766–75.
5. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–5.
6. Ibrahim ZA, Armour CL, Phipps S, Sukkar MB. RAGE and TLRs: relatives, friends or neighbours? Mol Immunol. 2013;56:739–44.
7. McCormack WJ, Parker AE, O’Neill LA. Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther. 2009;11:243.
8. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science. 2012;335:936–41.
9. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871–82.
10. Jacobs JJ, King TR, Klippel JH, Berven SH, Burr DB, Caskey PM, Elderkin AL, Esposito PW, Gall EP, Goldring SR, Pollak AN, Sandborg CI, Templeton KJ. Beyond the decade: strategic priorities to reduce the burden of musculoskeletal disease. J Bone Joint Surg Am. 2013;95:e1251–6.
11. Nho SJ, Kymes SM, Callaghan JJ, Felson DT. The burden of hip osteoarthritis in the United States: epidemiologic and economic considerations. J Am Acad Orthop Surg. 2013;21 Suppl 1:S1–6.
12. Collaborators USBoD. The state of US health, 1990- 2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310:591–608.
13. Schlee M. Master sensors of pathogenic RNA-RIG-I like receptors. Immunobiology. 2013;218:1322–35.
14. Thomas CJ, Schroder K. Pattern recognition receptor function in neutrophils. Trends Immunol. 2013;34:317–28.
15. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–7.
16. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29:447–91.
17. Carpenter S, Aiello D, Atianand MK, Ricci EP, Gandhi P, Hall LL, Byron M, Monks B, Henry-Bezy M, Lawrence JB, O’Neill LA, Moore MJ, Caffrey DR, Fitzgerald KA. A long noncoding RNA mediates both activation and repression of immune response genes. Science. 2013;341:789–92.
18. Chen X, Liang H, Zhang J, Zen K, Zhang CY. microRNAs are ligands of toll-like receptors. RNA. 2013;19:737–9.
19. Nibbs RJ, Graham GJ. Immune regulation by atypical chemokine receptors. Nat Rev Immunol. 2013;13:815–29.
20. Hoving JC, Wilson GJ, Brown GD. Signalling C-type lectin receptors, microbial recognition and immunity. Cell Microbiol. 2014;16:185–94.
21. Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol. 2012;30:491–529.
22. Kingeter LM, Lin X. C-type lectin receptor-induced NF-kappaB activation in innate immune and inflammatory responses. Cell Mol Immunol. 2012;9:105–12.
23. van Vliet SJ, Garcia-Vallejo JJ, van Kooyk Y. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol Cell Biol. 2008;86:580–7.
24. Sancho D, Reis e Sousa C. Sensing of cell death by myeloid C-type lectin receptors. Curr Opin Immunol. 2013;25:46–52.
25. Chuah YK, Basir R, Talib H, Tie TH, Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam. 2013;2013:403460.
26. Cohen MM Jr. Perspectives on RAGE signaling and its role in cardiovascular disease. Am J Med Genet A. 2013;161:2750–5.
27. Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci. 2011;36:625–32.
28. Sirois CM, Jin T, Miller AL, Bertheloot D, Nakamura H, Horvath GL, Mian A, Jiang J, Schrum J, Bossaller L, Pelka K, Garbi N, Brewah Y, Tian J, Chang C, Chowdhury PS, Sims GP, Kolbeck R, Coyle AJ, Humbles AA, Xiao TS, Latz E. RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med. 2013;210:2447–63.
29. Gallo PM and Gallucci S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol. 2013;4:138.
30. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013;93:865–73.
31. Brencicova E, Diebold SS. Nucleic acids and endosomal pattern recognition: how to tell friend from foe? Front Cell Infect Microbiol. 2013;3:37.
32. Paludan SR, Bowie AG. Immune sensing of DNA. Immunity. 2013;38:870–80.
33. Gurtler C, Bowie AG. Innate immune detection of microbial nucleic acids. Trends Microbiol. 2013;21:413–20.
34. Belibasakis GN, Guggenheim B, Bostanci N. Down-regulation of NLRP3 inflammasome in gingival fibroblasts by subgingival biofilms: involvement of Porphyromonas gingivalis. Innate Immun. 2013;19:3–9.
35. Zhong Y, Kinio A, Saleh M. Functions of NOD-Like Receptors in Human Diseases. Front Immunol. 2013;4:333.
36. Yazdi AS, Drexler SK. Regulation of interleukin 1alpha secretion by inflammasomes. Ann Rheum Dis. 2013;72 Suppl 2:ii 96–9.
37. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2013;39:1–19.
38. Aigner T, Schmitz N. Pathogenesis and pathology of osteoarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Elsevier (Mosby); 2011. p. 1741–59.
39. Reynard LN, Loughlin J. Insights from human genetic studies into the pathways involved in osteoarthritis. Nat Rev Rheumatol. 2013;9:573–83.
40. Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, Im HJ. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527:440–7.
41. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51:249–57.
42. Sohn DH, Sokolove J, Sharpe O, Erhart JC, Chandra PE, Lahey LJ, Lindstrom TM, Hwang I, Boyer KA, Andriacchi TP, Robinson WH. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via toll-like receptor 4. Arthritis Res Ther. 2012;14:R7.
43. Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, Millett PJ, Lee DM. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther. 2007;9:R36.
44. Siebuhr AS, Petersen KK, Arendt-Nielsen L, Egsgaard LL, Eskehave T, Christiansen C, Simonsen O, Hoeck HC, Karsdal MA, Bay-Jensen AC. Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. Osteoarthritis Cartilage. 2014;22:44–50.
45. Sillat T, Barreto G, Clarijs P, Soininen A, Ainola M, Pajarinen J, Korhonen M, Konttinen YT, Sakalyte R, Hukkanen M, Ylinen P, Nordstrom DC. Toll-like receptors in human chondrocytes and osteoarthritic cartilage. Acta Orthop. 2013;84:585–92.
46. Liu-Bryan R, Terkeltaub R. The growing array of innate inflammatory ignition switches in osteoarthritis. Arthritis Rheum. 2012;64:2055–8.
47. Madsen DH, Leonard D, Masedunskas A, Moyer A, Jurgensen HJ, Peters DE, Amornphimoltham P, Selvaraj A, Yamada SS, Brenner DA, Burgdorf S, Engelholm LH, Behrendt N, Holmbeck K, Weigert R, Bugge TH. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol. 2013;202:951–66.
48. Nair A, Kanda V, Bush-Joseph C, Verma N, Chubinskaya S, Mikecz K, Glant TT, Malfait AM, Crow MK, Spear GT, Finnegan A, Scanzello CR. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14. Arthritis Rheum. 2012;64:2268–77.
49. van Lent PL, Blom AB, Schelbergen RF, Sloetjes A, Lafeber FP, Lems WF, Cats H, Vogl T, Roth J, van den Berg WB. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum. 2012;64:1466–76.
50. Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S, Schreurs BW, Mort JS, Vogl T, Roth J, van den Berg WB, van Lent PL. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on toll-like receptor 4. Arthritis Rheum. 2012;64:1477–87.
51. Nakashima M, Sakai T, Hiraiwa H, Hamada T, Omachi T, Ono Y, Inukai N, Ishizuka S, Matsukawa T, Oda T, Takamatsu A, Yamashita S, Ishiguro N. Role of S100A12 in the pathogenesis of osteoarthritis. Biochem Biophys Res Commun. 2012;422:508–14.
52. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH. Identification of a central role for complement in osteoarthritis. Nat Med. 2011;17:1674–9.
53. Radwan M, Gavriilidis C, Robinson JH, Davidson R, Clark IM, Rowan AD, Young DA. Matrix metalloproteinase 13 expression in response to double-stranded RNA in human chondrocytes. Arthritis Rheum. 2013;65:1290–301.
54. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013;5:77–94.
55. Houard X, Goldring MB, Berenbaum F. Homeostatic mechanisms in articular cartilage and role of inflammation in osteoarthritis. Curr Rheumatol Rep. 2013;15:375.
56. Jin X, Beguerie JR, Zhang W, Blizzard L, Otahal P, Jones G, Ding C. Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. Published online 2013 Dec 20. doi:10.1136/annrheumdis-2013-204494.
57. Rigoglou S, Papavassiliou AG. The NF-kappaB signalling pathway in osteoarthritis. Int J Biochem Cell Biol. 2013;45:2580–4.
58. Konttinen YT, Sillat T, Barreto G, Ainola M, Nordstrom DC. Osteoarthritis as an autoinflammatory disease caused by chondrocyte-mediated inflammatory responses. Arthritis Rheum. 2012;64:613–6.
59. Vos PA, DeGroot J, Barten-van Rijbroek AD, Zuurmond AM, Bijlsma JW, Mastbergen SC, Lafeber FP. Elevation of cartilage AGEs does not accelerate initiation of canine experimental osteoarthritis upon mild surgical damage. J Orthop Res. 2012;30:1398–404.
60. Liao KP, Karlson EW. Classification and epidemiology of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Elsevier (Mosby); 2011. p. 823–8.
61. Brasington RD Jr. Clinical features of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Elsevier (Mosby); 2011. p. 829–38.
62. Klareskog L, Lundberg K, Malmstrom V. Autoimmunity in rheumatoid arthritis: citrulline immunity and beyond. Adv Immunol. 2013;118:129–58.
63. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstrom V, Feldmann M and Venables PJ. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233:34–54.
64. Chatzikyriakidou A, Voulgari PV, Lambropoulos A, Drosos AA. Genetics in rheumatoid arthritis beyond HLA genes: what meta-analyses have shown? Semin Arthritis Rheum. 2013;43:29–38.
65. Hill Gaston JS. Cellular immunity in rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Elsevier (Mosby); 2011. p. 897–903.
66. Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol. 2011;23:233–40.
67. Benedetti G and Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol. 2014; 44: 339–47.
68. Kouri VP, Olkkonen J, Ainola M, Li TF, Bjorkman L, Konttinen YT, Mandelin J. Neutrophils produce interleukin-17B in rheumatoid synovial tissue. Rheumatology (Oxford). 2014;53:39–47.
69. Zhu W, Meng L, Jiang C, He X, Hou W, Xu P, Du H, Holmdahl R, Lu S. Arthritis is associated with T-cell-induced upregulation of toll-like receptor 3 on synovial fibroblasts. Arthritis Res Ther. 2011;13:R103.
70. Carrion M, Juarranz Y, Martinez C, Gonzalez-Alvaro I, Pablos JL, Gutierrez-Canas I, Gomariz RP. IL-22/ IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2013;52:2177–86.
71. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20:62–8.
72. Tamaki Y, Takakubo Y, Hirayama T, Konttinen YT, Goodman SB, Yamakawa M, Takagi M. Expression of toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol. 2011;38:810–20.
73. Goh FG, Midwood KS. Intrinsic danger: activation of toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford). 2012;51:7–23.
74. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther. 2008;10:209.
75. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8:195–202.
76. He Z, Shotorbani SS, Jiao Z, Su Z, Tong J, Liu Y, Shen P, Ma J, Gao J, Wang T, Xia S, Shao Q, Wang S, Xu H. HMGB1 promotes the differentiation of Th17 via up-regulating TLR2 and IL-23 of CD14+ monocytes from patients with rheumatoid arthritis. Scand J Immunol. 2012;76:483–90.
77. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233–55.
78. Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, Poupot R, Cantagrel A. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013;52:590–8.
79. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33.
80. Boyle DL, Kim HR, Topolewski K, Bartok B, Firestein GS. Novel phosphoinositide 3-kinase delta,gamma inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. J Pharmacol Exp Ther. 2014;348:271–80.
81. Holzer A, Schroder C, Woiczinski M, Sadoghi P, Muller PE, Jansson V. The transport of wear particles in the prosthetic hip joint: a computational fluid dynamics investigation. J Biomech. 2012;45:602–4.
82. Zolotarevova E, Entlicher G, Pavlova E, Slouf M, Pokorny D, Vesely F, Gallo J, Sosna A. Distribution of polyethylene wear particles and bone fragments in periprosthetic tissue around total hip joint replacements. Acta Biomater. 2010;6:3595–600.
83. Urban RM, Jacobs JJ, Tomlinson MJ, Gavrilovic J, Black J, Peoc’h M. Dissemination of wear particles to the liver, spleen, and abdominal lymph nodes of patients with hip or knee replacement. J Bone Joint Surg Am. 2000;82:457–76.
84. Lewis CG, Sunderman FW Jr. Metal carcinogenesis in total joint arthroplasty. Animal models. Clin Orthop Relat Res. 1996;329 Suppl: S264–8.
85. Colognato R, Bonelli A, Ponti J, Farina M, Bergamaschi E, Sabbioni E, Migliore L. Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leukocytes in vitro. Mutagenesis. 2008;23:377–82.
86. Polyzois I, Nikolopoulos D, Michos I, Patsouris E, Theocharis S. Local and systemic toxicity of nanoscale debris particles in total hip arthroplasty. J Appl Toxicol. 2012;32:255–69.
87. Fahlgren A, Bostrom MP, Yang X, Johansson L, Edlund U, Agholme F, Aspenberg P. Fluid pressure and flow as a cause of bone resorption. Acta Orthop. 2010;81:508–16.
88. Gallo J, Goodman SB, Konttinen YT, Wimmer MA, Holinka M. Osteolysis around total knee arthroplasty: a review of pathogenetic mechanisms. Acta Biomater. 2013;9:8046–58.
89. Gallo J, Goodman SB, Konttinen YT, Raska M. Particle disease: biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty. Innate Immun. 2013;19:213–24.
90. Jiranek WA, Machado M, Jasty M, Jevsevar D, Wolfe HJ, Goldring SR, Goldberg MJ, Harris WH. Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg Am. 1993;75:863–79.
91. Kim KJ, Chiba J, Rubash HE. In vivo and in vitro analysis of membranes from hip prostheses inserted without cement. J Bone Joint Surg Am. 1994;76:172–80.
92. Dean DD, Schwartz Z, Blanchard CR, Liu Y, Agrawal CM, Lohmann CH, Sylvia VL, Boyan BD. Ultrahigh molecular weight polyethylene particles have direct effects on proliferation, differentiation, and local factor production of MG63 osteoblast-like cells. J Orthop Res. 1999;17:9–17.
93. Stea S, Visentin M, Granchi D, Melchiorri C, Soldati S, Sudanese A, Toni A, Montanaro L, Pizzoferrato A. Wear debris and cytokine production in the interface membrane of loosened prostheses. J Biomater Sci Polym Ed. 1999;10:247–57.
94. Kwon SY, Lin T, Takei H, Ma Q, Wood DJ, O’Connor D, Sung KL. Alterations in the adhesion behavior of osteoblasts by titanium particle loading: inhibition of cell function and gene expression. Biorheology. 2001;38:161–83.
95. Vermes C, Chandrasekaran R, Jacobs JJ, Galante JO, Roebuck KA, Glant TT. The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001;83-A:201–11.
96. Ingham E, Green TR, Stone MH, Kowalski R, Watkins N, Fisher J. Production of TNF-alpha and bone resorbing activity by macrophages in response to different types of bone cement particles. Biomaterials. 2000;21:1005–13.
97. Catelas I, Campbell PA, Dorey F, Frausto A, Mills BG, Amstutz HC. Semi-quantitative analysis of cytokines in MM THR tissues and their relationship to metal particles. Biomaterials. 2003;24:4785–97.
98. Shardlow DL, Stone MH, Ingham E, Fisher J. Cement particles containing radio-opacifiers stimulate pro-osteolytic cytokine production from a human monocytic cell line. J Bone Joint Surg Br. 2003;85:900–5.
99. Granchi D, Amato I, Battistelli L, Ciapetti G, Pagani S, Avnet S, Baldini N, Giunti A. Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles. Biomaterials. 2005;26:2371–9.
100. Brown C, Fisher J, Ingham E. Biological effects of clinically relevant wear particles from metal-on-metal hip prostheses. Proc Inst Mech Eng H. 2006;220:355–69.
101. Kaufman AM, Alabre CI, Rubash HE, Shanbhag AS. Human macrophage response to UHMWPE, TiAlV, CoCr, and alumina particles: analysis of multiple cytokines using protein arrays. J Biomed Mater Res A. 2008;84:464–74.
102. Nakashima Y, Sun DH, Trindade MC, Chun LE, Song Y, Goodman SB, Schurman DJ, Maloney WJ. Smith RL. Induction of macrophage C-C chemokine expression by titanium alloy and bone cement particles. J Bone Joint Surg Br. 1999;81:155–62.
103. Sun DH, Trindade MC, Nakashima Y, Maloney WJ, Goodman SB, Schurman DJ. Smith RL. Human serum opsonization of orthopedic biomaterial particles: protein-binding and monocyte/macrophage activation in vitro. J Biomed Mater Res A. 2003;65:290–8.
104. Fang HW, Yang CB, Chang CH, Huang CH, Liu HL, Fang SB. The potential role of phagocytic capacity in the osteolytic process induced by polyethylene wear particles. J Int Med Res. 2006;34:655–64.
105. Maloney WJ, Sun DH, Nakashima Y, James R, Smith RL. Effects of serum protein op-sonization on cytokine release by titanium-alloy particles. J Biomed Mater Res. 1998;41:371–6.
106. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, Smith RL. Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am. 1999;81:603–15.
107. Baumann B, Rader CP, Seufert J, Noth U, Rolf O, Eulert J, Jakob F. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. Acta Orthop Scand. 2004;75:295–302.
108. Masui T, Sakano S, Hasegawa Y, Warashina H, Ishiguro N. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Biomaterials. 2005;26:1695–702.
109. Chiu R, Ma T, Smith RL, Goodman SB. Ultrahigh molecular weight polyethylene wear debris inhibits osteoprogenitor proliferation and differentiation in vitro. J Biomed Mater Res A. 2009;89:242–7.
110. Wang CT, Lin YT, Chiang BL, Lee SS, Hou SM. Over-expression of receptor activator of nuclear factor-kappaB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials. 2010;31:77–82.
111. Hirashima Y, Ishiguro N, Kondo S, Iwata H. Osteoclast induction from bone marrow cells is due to pro-inflammatory mediators from macrophages exposed to polyethylene particles: a possible mechanism of osteolysis in failed THA. J Biomed Mater Res. 2001;56:177–83.
112. Gallo J, Raska M, Mrazek F, Petrek M. Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis. Physiol Res. 2008;57:339–49.
113. Gallo J, Slouf M, Goodman SB. The relationship of polyethylene wear to particle size, distribution, and number: A possible factor explaining the risk of osteolysis after hip arthroplasty. J Biomed Mater Res B Appl Biomater. 2010;94:171–7.
114. Orishimo KF, Claus AM, Sychterz CJ, Engh CA. Relationship between polyethylene wear and osteolysis in hips with a second-generation porous-coated cementless cup after seven years of follow-up. J Bone Joint Surg Am. 2003;85:A 1095–9.
115. von Knoch M, Jewison DE, Sibonga JD, Sprecher C, Morrey BF, Loer F, Berry DJ, Scully SP. The effectiveness of polyethylene versus titanium particles in inducing osteolysis in vivo. J Orthop Res. 2004;22:237–43.
116. Petit A, Catelas I, Antoniou J, Zukor DJ, Huk OL. Differential apoptotic response of J774 macrophages to alumina and ultra-high-molecular-weight polyethylene particles. J Orthop Res. 2002;20:9–15.
117. Catelas I, Jacobs JJ. Biologic activity of wear particles. Instr Course Lect. 2010;59:3–16.
118. Illgen RL 2nd, Bauer LM, Hotujec BT, Kolpin SE, Bakhtiar A, Forsythe TM. Highly crosslinked vs conventional polyethylene particles: relative in vivo inflammatory response. J Arthroplasty. 2009;24:117–24.
119. Baxter RM, MacDonald DW, Kurtz SM, Steinbeck MJ. Characteristics of highly cross-linked polyethylene wear debris in vivo. J Biomed Mater Res B. 2013;101:467–75.
120. Green TR, Fisher J, Stone M, Wroblewski BM, Ingham E. Polyethylene particles of a ‘critical size’ are necessary for the induction of cytokines by macrophages in vitro. Biomaterials. 1998;19:2297–302.
121. Yang SY, Ren W, Park Y, Sieving A, Hsu S, Nasser S, Wooley PH. Diverse cellular and apoptotic responses to variant shapes of UHMWPE particles in a murine model of inflammation. Biomaterials. 2002;23:3535–43.
122. Baumann B, Rolf O, Jakob F, Goebel S, Sterner T, Eulert J, Rader CP. Synergistic effects of mixed TiAlV and polyethylene wear particles on TNFalpha response in THP-1 macrophages. Biomed Tech (Berl). 2006;51:360–6.
123. Skoglund B, Larsson L, Aspenberg PA. Bone-resorptive effects of endotoxin-contaminated high-density polyethylene particles spontaneously eliminated in vivo. J Bone Joint Surg Br. 2002;84:767–73.
124. Tatro JM, Taki N, Islam AS, Goldberg VM, Rimnac CM, Doerschuk CM, Stewart MC, Greenfield EM. The balance between endotoxin accumulation and clearance during particle-induced osteolysis in murine calvaria. J Orthop Res. 2007;25:361–9.
125. Wilkins R, Tucci M, Benghuzzi H. Evaluation of endotoxin binding to uhmwpe and inflammatory mediator production by macrophages. Biomed Sci Instrum. 2008;44:459–64.
126. Bi Y, Seabold JM, Kaar SG, Ragab AA, Goldberg VM, Anderson JM, Greenfield EM. Adherent endotoxin on orthopedic wear particles stimulates cytokine production and osteoclast differentiation. J Bone Miner Res. 2001;16:2082–91.
127. Daniels AU, Barnes FH, Charlebois SJ, Smith RA. Macrophage cytokine response to particles and lipopolysaccharide in vitro. J Biomed Mater Res. 2000;49:469–78.
128. Cho DR, Shanbhag AS, Hong CY, Baran GR, Goldring SR. The role of adsorbed endotoxin in particle-induced stimulation of cytokine release. J Orthop Res. 2002;20:704–13.
129. McEvoy A, Jeyam M, Ferrier G, Evans CE, Andrew JG. Synergistic effect of particles and cyclic pressure on cytokine production in human monocyte/ macrophages: proposed role in periprosthetic osteolysis. Bone. 2002;30:171–7.
130. Matthews JB, Mitchell W, Stone MH, Fisher J, Ingham E. A novel three-dimensional tissue equivalent model to study the combined effects of cyclic mechanical strain and wear particles on the osteolytic potential of primary human macrophages in vitro. Proc Inst Mech Eng H. 2001;215:479–86.
131. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469–78.
132. Maitra R, Clement CC, Scharf B, Crisi GM, Chitta S, Paget D, Purdue PE, Cobelli N, Santambrogio L. Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis. Mol Immunol. 2009;47:175–84.
133. Hao HN, Zheng B, Nasser S, Ren W, Latteier M, Wooley P, Morawa L. The roles of monocytic heat shock protein 60 and toll-like receptors in the regional inflammation response to wear debris particles. J Biomed Mater Res A. 2010;92:1373–81.
134. Valladares RD, Nich C, Zwingenberger S, Li C, Swank KR, Gibon E, Rao AJ, Yao Z, Goodman SB. Toll-like receptors-2 and 4 are overexpressed in an experimental model of particle-induced osteolysis. J Biomed Mater Res A. 2014;102:3004–11.
135. Pajarinen J, Mackiewicz Z, Pollanen R, Takagi M, Epstein NJ, Ma T, Goodman SB, Konttinen YT. Titanium particles modulate expression of toll-like receptor proteins. J Biomed Mater Res A. 2010;92:1528–37.
136. Hirayama T, Tamaki Y, Takakubo Y, Iwazaki K, Sasaki K, Ogino T, Goodman SB, Konttinen YT, Takagi M. Toll-like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide-coated titanium particles. J Orthop Res. 2011;29:984–92.
137. Takagi M, Tamaki Y, Hasegawa H, Takakubo Y, Konttinen L, Tiainen VM, Lappalainen R, Konttinen YT, Salo J. Toll-like receptors in the interface membrane around loosening total hip replacement implants. J Biomed Mater Res A. 2007;81:1017-26.
138. Pearl JI, Ma T, Irani AR, Huang Z, Robinson WH, Smith RL, Goodman SB. Role of the toll-like receptor pathway in the recognition of orthopedic implant wear-debris particles. Biomaterials. 2011;32:5535–42.
139. Caicedo MS, Desai R, McAllister K, Reddy A, Jacobs JJ, Hallab NJ. Soluble and part-iculate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity. J Orthop Res. 2009;27:847–54.
140. Burton L, Paget D, Binder NB, Bohnert K, Nestor BJ, Sculco TP, Santambrogio L, Ross FP, Goldring SR, Purdue PE. Orthopedic wear debris mediated inflammatory osteolysis is mediated in part by NALP3 inflammasome activation. J Orthop Res. 2013;31:73–80.
141. Caicedo MS, Samelko L, McAllister K, Jacobs JJ, Hallab NJ. Increasing both CoCrMo-alloy particle size and surface irregularity induces increased macrophage inflammasome activation in vitro potentially through lysosomal destabilization mechanisms. J Orthop Res. 2013;31:1633–42.
142. Greenfield EM, Tatro JM, Smith MV, Schnaser EA, Wu D. PI3Kgamma deletion reduces variability in the in vivo osteolytic response induced by orthopaedic wear particles. J Orthop Res. 2011;29:1649–53.
143. Yamanaka Y, Abu-Amer Y, Faccio R, Clohisy JC. Map kinase c-JUN N-terminal kinase mediates PMMA induction of osteoclasts. J Orthop Res. 2006;24:1349–57.
144. Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y. Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J Orthop Res. 2006;24:1358–65.
145. Zhang Y, Hou C, Yu S, Xiao J, Zhang Z, Zhai Q, Chen J, Li Z, Zhang X, Lehto M, Konttinen YT, Sheng P. IRAK-M in macrophages around septically and aseptically loosened hip implants. J Biomed Mater Res A. 2012;100:261–8.
146. Brochu C, Cabrita MA, Melanson BD, Hamill JD, Lau R, Pratt MA, McKay BC. NF-kappaB-dependent role for cold-inducible RNA binding protein in regulating interleukin 1beta. PLoS One. 2013;8:e57426.
147. Bidwell JP, Yang J, Robling AG. Is HMGB1 an osteocyte alarmin? J Cell Biochem. 2008;103:1671–80.
148. Ren W, Yang SY, Wooley PH. A novel murine model of orthopaedic wear-debris associated osteolysis. Scand J Rheumatol. 2004;33:349–57.
149. Yang SY, Yu H, Gong W, Wu B, Mayton L, Costello R, Wooley PH. Murine model of prosthesis failure for the long-term study of aseptic loosening. J Orthop Res. 2007;25:603–11.
150. Ren W, Wu B, Peng X, Hua J, Hao HN, Wooley PH. Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK(-/-) mice. J Orthop Res. 2006;24:1575–86.
151. Ren W, Markel DC, Schwendener R, Ding Y, Wu B, Wooley PH. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. J Biomed Mater Res A. 2008;85:1043–51.
152. Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B, Sgonc R, Wolfram D. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107–35.
153. Lisboa RA, Andrade MV, Cunha-Melo JR. Toll-like receptor activation and mechanical force stimulation promote the secretion of matrix metalloproteinases 1, 3 and 10 of human periodontal fibroblasts via p38, JNK and NF-kB. Arch Oral Biol. 2013;58:731–9.
154. Qian Y, Zhang XL, Zeng BF, Jiang Y, Shen H, Wang Q. Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane. Connect Tissue Res. 2013;54:361–6.
155. Chan E, Cadosch D, Gautschi OP, Sprengel K, Filgueira L. Influence of metal ions on human lymphocytes and the generation of titanium-specific T-lymphocytes. J Appl Biomater Biomech. 2011;9:137–43.
156. Chan EP, Mhawi A, Clode P, Saunders M, Filgueira L. Effects of titanium(iv) ions on human monocyte-derived dendritic cells. Metallomics. 2009;1:166–74.
157. Niissalo S, Li TF, Santavirta S, Takagi M, Hietanen J, Konttinen YT. Dense innervation in pseudocapsular tissue compared to aneural interface tissue in loose totally replaced hips. J Rheumatol. 2002;29:796–803.
158. Mandelin J, Li TF, Hukkanen M, Liljestrom M, Salo J, Santavirta S, Konttinen YT. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. J Rheumatol. 2005;32:713–20.
159. Mediero A, Frenkel SR, Wilder T, He W, Mazumder A, Cronstein BN. Adenosine A2A receptor activation prevents wear particle-induced osteolysis. Sci Transl Med. 2012;4:135-65.
160. Yamanaka Y, Clohisy JC, Ito H, Matsuno T, Abu-Amer Y. Blockade of JNK and NFAT pathways attenuates orthopedic particle-stimulated osteoclastogenesis of human osteoclast precursors and murine calvarial osteolysis. J Orthop Res. 2013;31:67–72.
161. Alhawagri M, Yamanaka Y, Ballard D, Oltz E, Abu- Amer Y. Lysine392, a K63-linked ubiquitination site in NEMO, mediates inflammatory osteoclastogenesis and osteolysis. J Orthop Res. 2012;30:554–60.
162. Shah NJ, Hyder MN, Moskowitz JS, Quadir MA, Morton SW, Seeherman HJ, Padera RF, Spector M, Hammond PT. Surface-mediated bone tissue morphogenesis from tunable nanolayered implant coatings. Sci Transl Med. 2013;5:191-83.
163. Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol. 2011;11:221–30.
164. Hu W, Pasare C. Location, location, location: tissue-specific regulation of immune responses. J Leukoc Biol. 2013;94:409–21.
165. Murray PJ, Smale ST. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol. 2012;13:916–24.
166. De Jong PT, Tigchelaar W, Van Noorden CJ, Van der Vis HM. Polyethylene wear particles do not induce inflammation or gelatinase (MMP-2 and MMP-9) activity in fibrous tissue interfaces of loosening total hip arthroplasties. Acta Histochem. 2011;113:556–63.
167. Gordon A, Greenfield EM, Eastell R, Kiss-Toth E, Wilkinson JM. Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to pro-inflammatory stimuli. J Orthop Res. 2010;28:1127–35.
168. Gallo J, Mrazek F, Petrek M. Variation in cytokine genes can contribute to severity of acetabular osteolysis and risk for revision in patients with ABG 1 total hip arthroplasty: a genetic association study. BMC Med Genet. 2009;10:109.
169. Vasudevan A, DiCarlo EF, Wright T, Chen D, Figgie MP, Goldring SR and Mandl LA. Cellular response to prosthetic wear debris differs in patients with and without rheumatoid arthritis. Arthritis Rheum. 2012;64:1005–14.
170. Zhou Z and Xiong WC. RAGE and its ligands in bone metabolism. Front Biosci (Schol Ed). 2011;3:768–76.
171. Valles G, Garcia-Cimbrelo E, Vilaboa N. Involvement of extracellular Hsp72 in wear particle-mediated osteolysis. Acta Biomater. 2012;8:1146–55.
172. Lv YW, Wang J, Sun L, Zhang JM, Cao L, Ding YY, Chen Y, Dou JJ, Huang J, Tang YF, Wu WT, Cui WR, Lv HT. Understanding the pathogenesis of Kawasaki disease by network and pathway analysis. Comput Math Methods Med. 2013;2013:989307.
173. Kim KJ, Kobayashi Y, Itoh T. Osteolysis model with continuous infusion of polyethylene particles. Clin Orthop Relat Res. 1998:352:46–52.
174. Ortiz SG, Ma T, Epstein NJ, Smith RL, Goodman SB. Validation and quantification of an in vitro model of continuous infusion of submicron-sized particles. J Biomed Mater Res B Appl Biomater. 2008;84:328–33.
175. Ortiz SG, Ma T, Regula D, Smith RL, Goodman SB. Continuous intramedullary polymer particle infusion using a murine femoral explant model. J Biomed Mater Res B. 2008;87:440–6.
176. Ren PG, Irani A, Huang Z, Ma T, Biswal S, Goodman SB. Continuous infusion of UHMWPE particles induces increased bone macrophages and osteolysis. Clin Orthop Relat Res. 2011;469:113–22.
177. Chamberlain ND, Kim SJ, Vila OM, Volin MV, Volkov S, Pope RM, Arami S, Mandelin AM 2nd, Shahrara S. Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNFalpha in monocytes. Ann Rheum Dis. 2013;72:418–26.
178. Carrion M, Juarranz Y, Perez-Garcia S, Jimeno R, Pablos JL, Gomariz RP, Gutierrez-Canas I. RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum. 2011;63:1626–36.
179. Karpus ON, Heutinck KM, Wijnker PJ, Tak PP, Hamann J. Triggering of the dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial fibroblasts. PLoS One. 2012;7:e35606.
180. Franke S, Sommer M, Ruster C, Bondeva T, Marticke J, Hofmann G, Hein G, Wolf G. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther. 2009;11:R136.
181. Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar- Hernandez MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25:2185–97.